{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:21:31Z","timestamp":1790626891796,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.104942","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T16:02:37Z","timestamp":1691942557000},"page":"104942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0328-657X","authenticated-orcid":false,"given":"Augustin","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Kolitsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lanotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Sellal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Gaultier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Courtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohrab","family":"Mostoufizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Dentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Bigaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104942_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458518754364","article-title":"Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: a multicentre, Italian, retrospective, observational study","volume":"25","author":"Baroncini","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104942_bib0021","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaneurol.2021.1008","article-title":"Risk of persistent disability in patients with pediatric-onset multiple sclerosis","volume":"78","author":"Baroncini","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0009","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104942_bib0014","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/brain\/awaa199","article-title":"Improved relapse recovery in paediatric compared to adult multiple sclerosis","volume":"143","author":"Chitnis","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104942_bib0001","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ana.26052","article-title":"Early predictors of 9-year disability in pediatric multiple sclerosis","volume":"89","author":"De Meo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2352-4642(18)30026-9","article-title":"MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study","volume":"2","author":"Fadda","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.msard.2023.104942_bib0018","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1212\/NXI.0000000000000591","article-title":"Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS","volume":"6","author":"Ghezzi","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104942_bib0002","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0016","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archneur.65.12.1655","article-title":"Natalizumab use in pediatric multiple sclerosis","volume":"65","author":"Huppke","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0006","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458517732843","article-title":"Therapy of highly active pediatric multiple sclerosis","volume":"25","author":"Huppke","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104942_bib0015","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458519846100","article-title":"Predictors of treatment outcome in patients with paediatric onset multiple sclerosis","volume":"26","author":"Kopp","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104942_bib0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","article-title":"Natalizumab therapy for highly active pediatric multiple sclerosis","volume":"70","author":"Kornek","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00415-019-09554-z","article-title":"No evidence of disease activity including cognition (NEDA-3 plus) in na\u00efve pediatric multiple sclerosis patients treated with natalizumab","volume":"267","author":"Margoni","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737175.2022.2064743","article-title":"Pediatric multiple sclerosis: developments in timely diagnosis and prognostication","volume":"22","author":"Margoni","year":"2022","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.msard.2023.104942_bib0004","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaneurol.2019.1546","article-title":"Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis","volume":"76","author":"McKay","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0022","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.1212\/WNL.0000000000008667","article-title":"Determinants of quality of life in pediatric- and adult-onset multiple sclerosis","volume":"94","author":"McKay","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104942_bib0013","unstructured":"Medistica. pvalue.io, a Graphic User Interface to the R statistical analysis software for scientific medical publications. PvalueIo 2022. https:\/\/www.pvalue.io (accessed January 6, 2023)."},{"key":"10.1016\/j.msard.2023.104942_bib0008","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1212\/NXI.0000000000001008","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the united kingdom","volume":"8","author":"OA","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104942_bib0012","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104942_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30439","article-title":"Effect of dimethyl fumarate VS Interferon \u03b2-1a in patients with pediatric-onset multiple sclerosis: the CONNECT randomized clinical trial","volume":"5","author":"Vermersch","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.msard.2023.104942_bib0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"Von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2023.104942_bib0003","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:02:49Z","timestamp":1727452969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823004431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":23,"alternative-id":["S2211034823004431"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104942","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104942"}}